

PHARMING INITIATES EQUITY FUNDRAISING

*NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO
OR IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA.*

Leiden, The Netherlands, May 27, 2010. Biotech company Pharming Group NV ("Pharming") (NYSE Euronext: PHARM) announced on April 22, 2010 to investigate the possibilities of attracting additional funding. Today, Pharming announces that it has received a number of pre-commitments from existing and new shareholders to participate in an intended equity offering of up to €12 million, by means of a private placement with institutional investors and qualifying investors who subscribe for a minimum amount of €50,000.

The net proceeds of such offering will be used for corporate activities, most notably for the ongoing regulatory approval processes and start of commercialization of Rhucin for the treatment of Hereditary Angioedema, and selective development of subsequent indications of rhC1 inhibitor.

Pharming expects to be able to make further announcements on the intended offering shortly.

About Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, and nutritional products. Pharming's lead product Rhucin® for acute attacks of Hereditary Angioedema has passed clinical development stage and the Market Authorization Application is under review with the European Medicines Agency. Prodarsan® - a product under development by Pharming's subsidiary DNage - is in early stage clinical development for Cockayne Syndrome and lactoferrin for use in food products. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technology in the field of DNA repair (via DNage). Recently the partial spin-out of DNage was initiated. Additional information is available on the Pharming website, <http://www.pharming.com>.

Not for distribution, directly or indirectly, in or into the United States, Australia, Canada, Japan or South Africa or to US persons. This announcement is not a prospectus and does not contain or constitute an offer for sale or the solicitation of an offer to purchase securities in the United States, Australia, Canada, Japan or South Africa or any other jurisdiction.

The securities mentioned herein have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration under the Securities Act or an available exemption from, or to or for the account of US persons (as such term is defined in Regulation S under the Securities Act) or transaction not subject to, the registration requirements of the Securities Act.

In the event that an offering will be pursued, a prospectus will be made generally available in connection with the admission of the offered shares in the capital of the Company to trading on Euronext Amsterdam by NYSE Euronext, copies of which will then be available at no cost through the website of Euronext Amsterdam (Dutch residents only) and by sending a request in writing to the Company.

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.

Contact:

Sijmen de Vries, Pharming Group NV, T: +31 (0)71 52 47 431 or +31 (0)6 109 299 54